Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9257-08.
Published April 1, 2026 · Recall initiated: March 17, 2026
Summary
FDA records drug Class II recall D-0404-2026, published April 1, 2026 and initiated March 17, 2026. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 1,897 Cartons; Lot: Lot: 4401619, Exp.: 09/30/2026; 4501005, 03/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
What to do
Voluntary: Firm initiated · Letter
Get an email if OCTREOTIDE ACETATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OCTREOTIDE ACETATE
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot: 4401619, Exp.: 09/30/2026; 4501005, 03/31/2027.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kitsMay 13, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial inApril 1, 2026
- FDALevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA,April 1, 2026
- FDACUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc,April 1, 2026
- FDAOctreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous orNovember 16, 2022
Questions about this recall
Was Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9257-08. recalled?
Yes. FDA published recall D-0404-2026 on April 1, 2026. Reported hazard: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OCTREOTIDE ACETATE.